National Medical Research Center of Children's Health of the Ministry of Health of the Russian Federation, 119991 Moscow, Russia.
Int J Mol Sci. 2024 Oct 18;25(20):11210. doi: 10.3390/ijms252011210.
The 5q Spinal Muscular Atrophy (SMA) is a hereditary autosomal recessive disease caused by defects in the survival motor neuron () gene encoding survival motor neuron (SMN) protein. Currently, it is the leading cause of infantile mortality worldwide. SMA is a progressive neurodegenerative disease with "continuum of clinical severity", which can be modulated by genetic and epigenetic factors known as disease modifiers (DMs). Individuals (even siblings) with the same defects in gene might have strikingly different types of SMA, supposedly due to the impact of DMs. There are several therapeutic options for SMA, all of them focusing on the restoration of the SMN protein levels to normal. Determining DMs and the pathways in which they are involved might aid in enhancing existing curative approaches. Furthermore, DMs might become novel therapeutic targets or prognostic biomarkers of the disease. This narrative review provides a brief overview of the genetics and pathobiology of SMA, and its bona fide modifiers. We describe novel, emerging DMs, approaches and tools used to identify them, as well as their potential mechanisms of action and impact on disease severity. We also propose several disease-modifying molecular mechanisms which could provide a partial explanation of the staggering variability of SMA phenotypes.
5q 型脊髓性肌萎缩症(SMA)是一种遗传性常染色体隐性疾病,由生存运动神经元(SMN)蛋白编码基因的生存运动神经元(SMN)基因缺陷引起。目前,它是全球婴儿死亡的主要原因。SMA 是一种进行性神经退行性疾病,具有“临床严重程度的连续性”,可以通过已知的疾病修饰因子(DMs)进行遗传和表观遗传调节。即使是携带相同 基因缺陷的个体(甚至是兄弟姐妹),也可能患有明显不同类型的 SMA,这可能归因于 DMs 的影响。目前有几种 SMA 的治疗选择,所有这些选择都侧重于将 SMN 蛋白水平恢复到正常水平。确定 DMs 及其参与的途径可能有助于增强现有的治疗方法。此外,DMs 可能成为该疾病的新型治疗靶点或预后生物标志物。本综述简要概述了 SMA 的遗传学和病理生物学及其真正的修饰因子。我们描述了新出现的 DM,用于识别它们的方法和工具,以及它们潜在的作用机制和对疾病严重程度的影响。我们还提出了几种疾病修饰的分子机制,这些机制可以部分解释 SMA 表型的巨大变异性。